Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease. In adding AD-Detect, a single-blood-draw ...

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the ...

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

With demand for COVID-19 tests rapidly drying up, testmakers like Quest Diagnostics are scrambling to find deeper waters that’ll keep them from running aground. Quest, for one, is banking on its core ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...

But even Labcorp and Quest have limits to how many test machines they can afford. As publicly traded companies that must return profits to shareholders, they can’t invest tens of millions of dollars ...

Starting today, people in the US can order the tests on Quest's consumer testing site without visiting a doctor. At $119, the kit is one of the more expensive offered on Quest's site. It requires a ...

"Quest's AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient," said ...